Back to top
more

Cardiovascular Systems, Inc. (CSII)

(Delayed Data from NSDQ)

$39.49 USD

39.49
435,746

+1.98 (5.28%)

Updated May 3, 2019 04:00 PM ET

After-Market: $39.52 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Cardiovascular Systems Rides on Launches Amid Coronavirus Woes

Cardiovascular Systems' (CSII) encouraging REACH PVI study outcome and launch of a physician finder are positives.

Cardiovascular Systems (CSII) Up 9.7% Since Last Earnings Report: Can It Continue?

Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Cardiovascular Systems (CSII) Q4 Loss Narrower Than Expected (Revised)

Cardiovascular Systems (CSII) registers significant decline in STEMI activations in Q4 earnings as patients avoid hospitals.

Cardiovascular Systems (CSII) Misses Q4 Earnings Estimates

Cardiovascular Systems (CSII) registers significant decline in STEMI activations in Q2 earnings as patients avoid hospitals.

Cardiovascular Systems (CSII) Reports Q4 Loss, Tops Revenue Estimates

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 2.27% and 10.49%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Cardiovascular Systems (CSII) Q4 Earnings Expected to Decline

Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cardiovascular Systems (CSII) Reports Q3 Loss, Lower Margin

Cardiovascular Systems (CSII) witnesses a significant decline in procedure volumes in Q3 for patients treated with orbital atherectomy devices.

Cardiovascular Systems (CSII) Reports Q3 Loss, Lags Revenue Estimates

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 11.11% and -4.42%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Cardiovascular Systems (CSII) to Report a Decline in Earnings: What to Look Out for

Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Cardiovascular Systems (CSII) Down 10.8% Since Last Earnings Report?

Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Cardiovascular Systems Grows on Domestic Sales Amid Margin Woe

Cardiovascular Systems (CSII) continues to register solid top-line growth on strength in the domestic atherectomy businesses.

Steer Clear Of These 5 Toxic Stocks Before It's Too Late

Figuring out bloated toxic stocks on a consistent basis and discarding them at the right time is the key to successful investing.

Cardiovascular Systems (CSII) Loss Wider Than Estimates in Q2

We are upbeat about Cardiovascular Systems' (CSII) year-over-year uptick in global Coronary and peripheral device revenues during Q2.

Cardiovascular Systems (CSII) Reports Q2 Loss, Tops Revenue Estimates

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -233.33% and 0.65%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Cardiovascular Systems (CSII) to Report a Decline in Earnings: What to Look Out for

Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cardiovascular Systems (CSII) Stock Hits New 52-Week High

Cardiovascular Systems (CSII) is optimistic about maintaining its growth momentum on several recent developments.

Cardiovascular Systems Sees Peripheral OAS Micro Crown Success

This is a major achievement for Cardiovascular Systems (CSII) toward strengthening its portfolio for the treatment of CLI.

Cardiovascular Systems (CSII) Up 6.2% Since Last Earnings Report: Can It Continue?

Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Cardiovascular Systems (CSII) Loss Wider Than Estimates in Q1

We are upbeat about the year-over-year uptick in both Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.

Cardiovascular Systems (CSII) Reports Q1 Loss, Tops Revenue Estimates

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -88.89% and 0.72%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Why Is Cardiovascular Systems (CSII) Up 1.8% Since Last Earnings Report?

Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Cardiovascular Systems Set to Present LIBERTY 360 Outcome

This study outcome is expected to be a major stride forward in Cardiovascular Systems' (CSII) endeavor to offer treatment to patients of multi-level peripheral artery disease (PAD).

Cardiovascular Systems (CSII) Earnings Match Estimates in Q4

We are upbeat about the year-over-year uptick in Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.

Cardiovascular Systems (CSII) Meets Q4 Earnings Estimates

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 0.00% and 3.32%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Cardiovascular Systems (CSII) Q4 Earnings Expected to Decline

Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.